Nippon Kayaku To Start Apaziquone Trials This Year
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku plans to start clinical study for apaziquone, an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation